Artica Therapeutics (Artica) is a biotechnology company dedicated to developing a pipeline of covalent small molecules to advance the treatment of autoimmune and inflammatory disorders. Covalent drugs bind irreversibly to their target by design and are thought to yield improved efficacy.

Artica was founded by Tjeerd Barf (co-founder and former executive Acerta Pharma), Arwin Ridder (former Astellas executive) and Prof. Ad IJzerman (academic GPCR expert)